Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin’s lymphoma

Mura, Vincenzo La; Renzo, Amalia De; Perna, Fabiana; D’Agostino, Diana; Masarone, Mario; Romano, Marco; Bruno, Savino; Torella, Roberto; Persico, Marcello

doi:10.1016/j.jhep.2008.06.025

Cited by 66 publications

(51 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found of a trend for an association between AT and OS in DLBCL patients. Antiviral treatment in HCV-positive NHL could reinforce the results of a successful chemotherapy regimen as previously proposed by La Mura et al [27]. Therefore, we suggest that, in DLBCL patients, AT should be proposed when lymphoma remission is obtained, taking into account the risk/benefit ratio of antiviral treatment.…”

Section: Discussionsupporting

confidence: 75%

Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study

et al. 2014

View full text Add to dashboard Cite

on behalf of the ANRS HC-13 Lympho-C Study Group Hepatitis C virus (HCV) infection increases the risk of B-cell non-Hodgkin lymphomas (B-NHL). Antiviral treatment (AT) can induce hematological responses in patients with marginal zone lymphomas (MZL). The ANRS HC-13 Lympho-C study aimed at a better understanding of the impact of AT on HCV associated B-NHL. This multicentric study enrolled 116 HCV-positive patients with B-NHL between 2006 and 2012. Cytological and histological samples were collected for centralized review. At lymphoma diagnosis, median age was 61 years and gender ratio M/F was 1. Cytohistological distribution was marginal zone lymphoma (MZL) n 5 45 (39%), diffuse large B-cell lymphoma (DLBCL) n 5 45 (39%), and other types n 5 26 (22%). MZL patients had more frequent detection of rheumatoid factor (68% vs. 35%; P 5 0.001) and more frequently mixed cryoglobulinemia (74% vs. 44%; P 5 0.021) than patients with DLBCL. Among patients receiving AT, a sustained virologic response was achieved in 23 of 38 (61%) patients with MZL and in 9 of 17 (53%) with DLBCL (P 5 0.42). Three-year overall survival (OS) and progression-free survival were 78% 95%CI and 64% , respectively, without difference between cytohistological groups. Outcome analysis showed a favorable association between OS and AT in all patients (P 5 0.05) and in the subgroup of MZL patients only (P 5 0.04). Our data support that AT improves the outcomes of HCV-associated NHLs. The impact of new AT regimen with protease inhibitor needs to be investigated in this setting. [clinicalTrials.gov Identification number NCT01545544]Am.

show abstract

Section: Discussionsupporting

confidence: 75%

Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Recent results suggest that antiviral therapy may be extended also to the treatment of aggressive lymphomas. 38 In most patients, antiviral treatment led also to disappearance of Ig heavy chain (Ig H C) and t(14;18) translocation. 39 Importantly, a recent study has shown that HCV-infected patients who had received interferon therapy and had undergone a sustained virologic response had a hazard ratio of lymphomagenesis that was significantly lower than patients who had not received antiviral treatment.…”

Section: Evidence For An Oncogenic Role Of Hcv In Nhlmentioning

confidence: 99%

Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities

Marcucci

Mele

2011

Blood

227

210

View full text Add to dashboard Cite

Over the past 2 decades considerable evidence has accumulated on the association between hepatitis C virus (HCV) and hepatitis B virus (HBV) and several hematologic malignancies, most notably B-cell non-Hodgkin lymphoma (NHL). In this review we summarize this evidence, address possible mechanisms whereby hepatitis viruses may contribute to lymphomagenesis, and discuss the therapeutic fallouts from this knowledge. Most of this evidence is on HCV, and this is the main focus of the review. Moreover, we mainly address the association with NHL, the most prevalent hematologic malignancy, and the most extensively investigated with regard to an association with hepatitis viruses. Available evidence on the association with other hematologic malignancies is also addressed briefly. (Blood. 2011;117(6):1792-1798) Hepatitis C virus and hepatitis B virusHepatitis C virus (HCV) is a positive, single-stranded RNA virus, member of the Flaviviridae family. 1 During its replicative cycle it goes through a negative-stranded RNA, but not DNA, intermediate, so that integration of HCV nucleic acid sequences into the host genome seems unlikely. As such, it lacks a pivotal property of classical oncogenic retroviruses. The HCV genome produces a single polyprotein that is proteolytically processed by viral and cellular proteases to produce structural (nucleocapsid, E1, E2) and nonstructural (NS) proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B).Hepatitis B virus (HBV) is a small DNA virus, member of the Hepadnaviridae family. 2 It presents the unusual feature, for a DNA virus, to replicate through a RNA intermediate and can integrate into the host genome. Moreover, during replication, it undergoes transformation into covalently closed circular DNA. Detection of closed circular DNA HBV-, or negative-stranded HCV-intermediates is important because it identifies genuine viral replication instead of more trivial events such as viral absorption. HBV is characterized by a genome consisting of 4 overlapping open-reading frames: the S gene, encoding envelope proteins; the core gene, encoding the core and "e" proteins; the P gene, encoding DNA polymerase; and the X gene, encoding a transcriptional transactivator.Both viruses can induce acute and chronic hepatitis and are strongly associated with hepatocellular carcinoma (HCC). Epidemiology of non-Hodgkin lymphomaNon-Hodgkin lymphoma (NHL) is the hematologic malignancy with the highest prevalence worldwide. Incidence rates have grown fast up to the beginning of the new millennium, with an annual percentage increase of nearly 3%, which is faster than for most cancers. Thus, delay-adjusted Surveillance, Epidemiology and End Results incidence rate for all races was 11.06/100 000 in 1975, and 20.12/100 000 in 2002. Since then, incidence rates have started to level off, at least in some geographic areas, such as the United States (20.89 in 2007). 3 NHL incidence rates are higher in developed countries such as those in western Europe, North America, and Australia and lower in South America and Asia, but th...

show abstract

“…In a retrospective study, 25 HCVpositive patients received antiviral treatment with interferon and ribavirin following completion of chemotherapy for non-Hodgkin's lymphoma. Among them none of the patients who achieved virological response experienced relapse of lymphoma, while 29 % of the non-responders relapsed [12].…”

Section: Discussionmentioning

confidence: 94%

Diagnostic and Therapeutic Quandaries in a Patient with Primary Hepatic Lymphoma and Concurrent Hepatitis C Infection

Mohamed

Fernando

2014

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Primary hepatic lymphoma (PHL) is a very rare sub-type of non-Hodgkin's lymphoma and hepatitis C infection may be a contributory factor. The association of hepatitis C infection and PHL causes difficulties in management since safety of rituximab in such situations is unclear due to lack of evidence. The role of anti-viral therapy in combination with chemotherapy is also uncertain. We describe the diagnostic and therapeutic challenges posed by a patient who was diagnosed with PHL and concurrent hepatitis C infection.

show abstract

Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin’s lymphoma

Cited by 66 publications

References 27 publications

Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study

Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study

Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities

Diagnostic and Therapeutic Quandaries in a Patient with Primary Hepatic Lymphoma and Concurrent Hepatitis C Infection

Contact Info

Product

Resources

About